You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParomomycin
Accession NumberDB01421
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Structure
Thumb
Synonyms
(1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
Aminosidin
Aminosidine
Catenulin
Crestomycin
Estomycin
Hydroxymycin
Monomycin a
Neomycin e
Paromomicina
PAROMOMYCIN
Paromomycin i
Paromomycine
Paromomycinum
Paucimycin
Paucimycinum
R 400
R-400
Zygomycin a1
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Humatin Cap 250mgcapsule250 mgoralErfa Canada 2012 Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Paromomycin Sulfatecapsule250 mg/1oralHeritage Pharmaceuticals Inc.2009-10-22Not applicableUs
Paromomycin Sulfatecapsule250 mg/1oralSun Pharmaceutical Industries, Inc.1997-06-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HumatinParke Davis (now Pfizer)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paromomycin sulfate
1263-89-4
Thumb
  • InChI Key: LJRDOKAZOAKLDU-UDXJMMFXSA-N
  • Monoisotopic Mass: 713.263680415
  • Average Mass: 713.707
DBSALT000265
Categories
UNII61JJC8N5ZK
CAS number7542-37-2
WeightAverage: 615.6285
Monoisotopic: 615.296301173
Chemical FormulaC23H45N5O14
InChI KeyInChIKey=UOZODPSAJZTQNH-LSWIJEOBSA-N
InChI
InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
SMILES
NC[C@@H]1O[[email protected]](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[[email protected]](N)C[[email protected]](N)[[email protected]]3O[[email protected]]3O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]3N)[C@@H]2O)[[email protected]](N)[C@@H](O)[C@@H]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • 4,5-disubstituted 2-deoxystreptamine
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Disaccharide
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Oxolane
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
PharmacodynamicsParomomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.
Mechanism of actionParomomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.
Related Articles
AbsorptionPoorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Paromomycin Action PathwayDrug actionSMP00714
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 mg
Capsuleoral250 mg/1
Prices
Unit descriptionCostUnit
Paromomycin 250 mg capsule5.67USD capsule
Humatin 250 mg capsule2.67USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility79.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-8.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)12.23ChemAxon
pKa (Strongest Basic)9.94ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area347.32 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity134.24 m3·mol-1ChemAxon
Polarizability60.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Federico Arcamone, Giuseppe Cassinelli, “Paromomycin derivatives and process for the preparation thereof.” U.S. Patent US4021601, issued October, 1967.

US4021601
General References
  1. Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001 Aug;9(8):647-58. [PubMed:11587639 ]
External Links
ATC CodesA07AA06
AHFS Codes
  • 08:30.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AceclofenacAceclofenac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Paromomycin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
AdapaleneAdapalene may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Alendronic acidParomomycin may increase the hypocalcemic activities of Alendronic acid.
AmdinocillinThe serum concentration of Paromomycin can be decreased when it is combined with Amdinocillin.
AmoxicillinThe serum concentration of Paromomycin can be decreased when it is combined with Amoxicillin.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Paromomycin.
AmpicillinThe serum concentration of Paromomycin can be decreased when it is combined with Ampicillin.
AntipyrineAntipyrine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ApremilastApremilast may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
AzapropazoneAzapropazone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
AzelastineAzelastine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
AzlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azlocillin.
BalsalazideBalsalazide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
BenoxaprofenBenoxaprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Benzathine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzathine benzylpenicillin.
BenzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicillin.
Benzylpenicillin PotassiumThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicillin Potassium.
Botulinum Toxin Type AParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.
Botulinum Toxin Type BParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
BromfenacBromfenac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paromomycin.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Paromomycin.
CarbenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Carbenicillin.
CarboplatinParomomycin may increase the ototoxic activities of Carboplatin.
CarprofenCarprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
CastanospermineCastanospermine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
CelecoxibCelecoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ChloroquineChloroquine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
CisplatinCisplatin may increase the nephrotoxic activities of Paromomycin.
ClodronateParomomycin may increase the hypocalcemic activities of Clodronate.
ClonixinClonixin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
CloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cloxacillin.
ColistimethateParomomycin may increase the nephrotoxic activities of Colistimethate.
CyclacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cyclacillin.
CyclosporineParomomycin may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.
DiclofenacDiclofenac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
DicloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Dicloxacillin.
DiflunisalDiflunisal may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Paromomycin.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Paromomycin.
DroxicamDroxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
EpirizoleEpirizole may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paromomycin.
EtanerceptEtanercept may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Etidronic acidParomomycin may increase the hypocalcemic activities of Etidronic acid.
EtodolacEtodolac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
EtofenamateEtofenamate may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
EtoricoxibEtoricoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Evening primrose oilEvening primrose oil may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
exisulindexisulind may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
FenbufenFenbufen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
FenoprofenFenoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
FloctafenineFloctafenine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
FlucloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Flucloxacillin.
FlunixinFlunixin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
FlurbiprofenFlurbiprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
FoscarnetFoscarnet may increase the nephrotoxic activities of Paromomycin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Paromomycin.
HMPL-004HMPL-004 may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateParomomycin may increase the hypocalcemic activities of Ibandronate.
IbuprofenIbuprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
IbuproxamIbuproxam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
IcatibantIcatibant may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
IndomethacinIndomethacin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
IndoprofenIndoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
IsoxicamIsoxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
KetoprofenKetoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacKetorolac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
LeflunomideLeflunomide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
LornoxicamLornoxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
LoxoprofenLoxoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
LumiracoxibLumiracoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
MannitolMannitol may increase the nephrotoxic activities of Paromomycin.
MasoprocolMasoprocol may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
MecamylamineParomomycin may increase the neuromuscular blocking activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Mefenamic acidMefenamic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
MeloxicamMeloxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
MesalazineMesalazine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
MetamizoleMetamizole may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
MeticillinThe serum concentration of Paromomycin can be decreased when it is combined with Meticillin.
MezlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Mezlocillin.
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
NabumetoneNabumetone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
NafcillinThe serum concentration of Paromomycin can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
NaproxenNaproxen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
NCX 4016NCX 4016 may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidNiflumic Acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
NimesulideNimesulide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
OlopatadineOlopatadine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
OlsalazineOlsalazine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
OrgoteinOrgotein may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Paromomycin.
OxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Oxacillin.
OxaprozinOxaprozin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PamidronateParomomycin may increase the hypocalcemic activities of Pamidronate.
ParecoxibParecoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PhenoxymethylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Phenoxymethylpenicillin.
PhenylbutazonePhenylbutazone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Paromomycin.
PimecrolimusPimecrolimus may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PiperacillinThe serum concentration of Paromomycin can be decreased when it is combined with Piperacillin.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Paromomycin.
PirfenidonePirfenidone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PiroxicamPiroxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PivampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Paromomycin can be decreased when it is combined with Pivmecillinam.
Procaine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Procaine benzylpenicillin.
PropacetamolPropacetamol may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PTC299PTC299 may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ResveratrolResveratrol may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateParomomycin may increase the hypocalcemic activities of Risedronate.
RofecoxibRofecoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SalicylamideSalicylamide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Salicylic acidSalicylic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SalsalateSalsalate may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SeratrodastSeratrodast may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SRT501SRT501 may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SulbactamThe serum concentration of Paromomycin can be decreased when it is combined with Sulbactam.
SulfasalazineSulfasalazine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SulindacSulindac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
SuprofenSuprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Technetium Tc-99m MedronateParomomycin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.
TenofovirThe serum concentration of Paromomycin can be increased when it is combined with Tenofovir.
TenoxicamTenoxicam may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
TepoxalinTepoxalin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
TeriflunomideTeriflunomide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
TicarcillinThe serum concentration of Paromomycin can be decreased when it is combined with Ticarcillin.
TiludronateParomomycin may increase the hypocalcemic activities of Tiludronate.
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
TolmetinTolmetin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Paromomycin.
TranilastTranilast may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ValdecoxibValdecoxib may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
VancomycinVancomycin may increase the nephrotoxic activities of Paromomycin.
ZaltoprofenZaltoprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ZileutonZileuton may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Zoledronic acidParomomycin may increase the hypocalcemic activities of Zoledronic acid.
ZomepiracZomepirac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
  • Take with food.

Targets

Kind
Protein
Organism
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Pharmacological action
yes
Actions
inhibitor
General Function:
Trna binding
Specific Function:
Part of the top of the 30S subunit head.
Gene Name:
rpsJ
Uniprot ID:
Q5SHN7
Molecular Weight:
11929.82 Da
References
  1. Dlugosz M, Trylska J: Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. doi: 10.1021/jp8112914. [PubMed:19438282 ]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
yes
Actions
inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Konno T, Kurita D, Takahashi T, Muto A, Himeno H: Initiation-shift of trans-translation by aminoglycosides. Nucleic Acids Symp Ser (Oxf). 2004;(48):299-300. [PubMed:17150597 ]
  4. Chao PW, Chow CS: Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem. 2007 Jun 1;15(11):3825-31. Epub 2007 Mar 13. [PubMed:17399988 ]
Comments
comments powered by Disqus
Drug created on July 24, 2007 04:03 / Updated on August 17, 2016 12:23